Since 2019 was a landmark year for compliance, we felt it appropriate as we begin our sixth publication year to feature a retrospective look at 2019’s Top 10 Compliance Milestones, and what they mean for 2020. In this issue, Katherine Norris and Jennifer Vondee provided a detailed analysis of the Top 5 developments. In the February issue, they will review the remainder of the Top 10.
For the remainder of this month’s Update, we expand on some of the developments highlighted in the feature. Thus, Gwedolyn Ball provides a year-end update on White House and Congressional efforts to address drug prices. Next, Robert Wilkey analyzes the partial reversal of the latest developments in the Insys case.
Looking Back on a Landmark Year: 2019’s Top Ten Compliance Milestones (and what they mean for 2020)
Drug Pricing Year-End Wrap Up – Lots of Activity, But Little Real Reform
Redressing Corporate Misdeeds – Is Holding Individuals Accountable the Answer?
It’s Still Not Over – Judge Partially Reverses Convictions of Insys Executives